Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jiangsu Aoyang Health Industry Co.ltd. (002172.SZ)
Zhangjiagang, CN
Jiangsu Aoyang Health Industry Co.ltd. is a multifaceted enterprise primarily engaged in two key sectors: chemical fiber manufacturing and healthcare services. Globally, the company manufactures and distributes a range of chemical fibers, including advanced functional fibers and traditional viscose varieties. Complementing its industrial activities, Aoyang Health maintains a significant presence in the health sector. This includes the operation of hospitals, rehabilitation facilities, and retail pharmaceutical outlets. Furthermore, its healthcare portfolio extends to offering comprehensive health management solutions, managing pharmaceutical logistics, and distributing medical products. Established in 2001 and headquartered in Zhangjiagang, China, the entity underwent a name change in September 2018, transitioning from its previous designation, Jiangsu Aoyang Technology Corporation Limited, to its current identity.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.48% | -4.05% | -13.32% | -26.55% | -22.61% | -16.37% | -9.29% | -4.05% | -49.54% | -68.53% | -73.12% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-10.1% Q1'26: -10.0% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+14.8% ★ Q1'26: -50.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-3.7% Q1'26: +6.6% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+4.9% Q1'26: +3.9% (vs Q1'25)
-
ROIC Chemicals: +3.4%+12.8% ★ Q1'26: +6.8% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-11.4% ★ Q1'26: -43.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×4.87× Q1'26: 12.16× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 5/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chao Ji | Secretary of the Board & Non-Independent Director | — | male |
| Jing Li | Vice Chairman & GM | — | female |
| Wei Wang | Deputy General Manager | — | male |
| Xia Li | Financial Director & Accounting Supervisor | — | female |
| Zhihao Zhu | Deputy GM & Non-Independent Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002172.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
